The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The treatment of MPNs in the United Kingdom’s NHS framework
Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, briefly outlines the agents used for the treatment of myeloproliferative neoplasms (MPNs) within the United Kingdom’s NHS framework. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Myeloproliferative neoplasms are treated in the NHS in the UK and there’s a range of different types of MPN. So for essential thrombocythemia, the standard treatments available are hydroxycarbamide and pegylated interferon treatment with anagrelide treatment for some patients. In polycythemia vera the same treatments are available but we also have access to JAK2 inhibitor treatment with ruxolitinib for patients who are intolerant or resistant to hydroxycarbamide...
Myeloproliferative neoplasms are treated in the NHS in the UK and there’s a range of different types of MPN. So for essential thrombocythemia, the standard treatments available are hydroxycarbamide and pegylated interferon treatment with anagrelide treatment for some patients. In polycythemia vera the same treatments are available but we also have access to JAK2 inhibitor treatment with ruxolitinib for patients who are intolerant or resistant to hydroxycarbamide. In myelofibrosis, a more advanced form of myeloproliferative neoplasm, we’re now lucky enough to have access both to ruxolitinib and two other JAK2 inhibitor treatments, fedratinib and momelotinib treatment. So we’ve got a much wider arsenal of different treatments available.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Incyte: Consultancy, Honoraria; Alethiomics: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company, Research Funding; GSK: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria; Medscape: Honoraria; Ionis: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Galecto: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Roche: Research Funding.
